NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $4.08 -0.16 (-3.77%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.98▼$4.3150-Day Range$3.56▼$4.8952-Week Range$2.68▼$7.28Volume235,527 shsAverage Volume344,236 shsMarket Capitalization$130.47 millionP/E RatioN/ADividend YieldN/APrice Target$21.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Capricor Therapeutics alerts: Email Address Capricor Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside433.1% Upside$21.75 Price TargetShort InterestBearish21.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.24) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 starsMedical Sector744th out of 910 stocksPharmaceutical Preparations Industry350th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.89% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 12.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CAPR. Previous Next 2.6 News and Social Media Coverage News SentimentCapricor Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 11.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Capricor Therapeutics Stock (NASDAQ:CAPR)Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More CAPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CAPR Stock News HeadlinesSeptember 6 at 8:30 AM | globenewswire.comCapricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesSeptember 3, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for Alnylam Pharma (ALNY)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 3, 2024 | americanbankingnews.comCapricor Therapeutics Inc (NASDAQ:CAPR) Short Interest UpdateAugust 10, 2024 | markets.businessinsider.comCapricor Therapeutics’ Strong Potential Justifies Buy Rating Amidst Strategic Progress and Positive Clinical DevelopmentsAugust 10, 2024 | finance.yahoo.comThings Look Grim For Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Today's DowngradeAugust 9, 2024 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finance.yahoo.comCapricor Therapeutics Second Quarter 2024 Earnings: Beats ExpectationsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 9, 2024 | msn.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Capricor Therapeutics Amidst Positive Drug Outlook and Strategic AdvancesAugust 7, 2024 | msn.comCapricor Therapeutics GAAP EPS of -$0.35 beats by $0.01, revenue of $3.97M beats by $0.31MAugust 7, 2024 | finance.yahoo.comCapricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 31, 2024 | msn.comPepGen stock tumbles 25% following release of DMD drug dataJuly 31, 2024 | finance.yahoo.comCapricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7June 25, 2024 | globenewswire.comCORRECTION: Capricor TherapeuticsJune 25, 2024 | globenewswire.comCapricor Therapeutics Announces for the Treatment of Duchenne Muscular DystrophyMay 22, 2024 | finance.yahoo.comCapricor Therapeutics (NASDAQ:CAPR) shareholder returns have been stellar, earning 113% in 5 yearsSee More Headlines Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$21.75 High Stock Price Target$40.00 Low Stock Price Target$8.00 Potential Upside/Downside+433.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-102.93% Pretax Margin-102.93% Return on Equity-220.27% Return on Assets-60.88% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.37 Sales & Book Value Annual Sales$27.15 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book11.66Miscellaneous Outstanding Shares31,979,000Free Float28,142,000Market Cap$130.47 million OptionableOptionable Beta4.00 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More ExecutivesKey CompetitorsClearside BiomedicalNASDAQ:CLSDLeap TherapeuticsNASDAQ:LPTXProPhase LabsNASDAQ:PRPHEyenoviaNASDAQ:EYENNeuroBo PharmaceuticalsNASDAQ:NRBOView All CompetitorsInsiders & InstitutionsMarshall Wace LLPBought 89,314 shares on 8/14/2024Ownership: 0.279%Renaissance Technologies LLCBought 84,350 shares on 8/9/2024Ownership: 0.430%Main Street Financial Solutions LLCBought 7,500 shares on 8/8/2024Ownership: 0.086%Rhumbline AdvisersBought 30,886 shares on 8/1/2024Ownership: 0.097%Bank of New York Mellon CorpBought 9,040 shares on 7/26/2024Ownership: 0.249%View All Insider TransactionsView All Institutional Transactions CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $4.89 at the start of the year. Since then, CAPR shares have decreased by 16.6% and is now trading at $4.08. View the best growth stocks for 2024 here. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.03. The biotechnology company earned $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 220.27% and a negative net margin of 102.93%. Who are Capricor Therapeutics' major shareholders? Top institutional shareholders of Capricor Therapeutics include Renaissance Technologies LLC (0.43%), Marshall Wace LLP (0.28%), Bank of New York Mellon Corp (0.25%) and Rhumbline Advisers (0.10%). Insiders that own company stock include David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN) and Dynavax Technologies (DVAX). This page (NASDAQ:CAPR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAPR Stock Alerts